We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

News · June 06, 2022

ASCO 2022: MET and CTLA-4 Inhibition Fail to Add Benefit to Durvalumab Therapy in Advanced Clear Cell Renal Cancer

Benefits of MET inhibition were not in evidence, even in MET-driven tumors

PracticeUpdate Editorial Team


Further Reading